Friday 08 May 2020
New York (AP)
A new study conducted by hospitals in New York showed that administering Covid-19 patients in a risk situation with hydroxychloroquine used to treat malaria did not improve their condition or make it significantly worse.
The authors of the study, published in the New England Journal of Medicine, said that “the risk of death or insertion of a tube into the trachea in patients who received hydrochloroquine compared to those who did not receive it did not decrease or increase significantly.”
A surveillance study, funded by the US Institutes of Health, was conducted on Covid-19 patients admitted to the emergency department of two hospitals in New York.
811 patients received two doses of 600 milligrams of hydroxychloroquine on the first day and then 400 milligrams per day over a period of four days.
565 patients did not receive the drug.
Scientists stressed that this study “should not be used to exclude” the pros or possible risks of hydroxychloroquine therapy.
“However, our results do not support the use of hydroxychloroquine at present outside of randomized clinical trials (by selecting patients by lottery) to demonstrate its effectiveness,” they added.
US President Donald Trump has regularly supported the use of hydroxychloroquine as a treatment for Covid-19 patients. But US and Canadian health authorities have warned against using it outside the framework of clinical trials.
Hydroxychloroquine and chlorine have been used for years to treat malaria and some autoimmune diseases such as lupus and rheumatoid arthritis.